Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
1. Jade Biosciences has begun Phase 1 trial for JADE101 targeting IgAN. 2. Interim data is expected in the first half of 2026. 3. JADE101 shows potential for patient-friendly dosing and significant effectiveness. 4. Differentiated pharmacokinetic profile suggests potential market competitiveness. 5. Clinical trials may face delays and uncertainties according to company disclaimers.